Narrow By

Press releases

1 2 3 30

BD Statement on FDA Recommendations to Health Care Providers Regarding Paclitaxel-Coated Devices

Aug 9, 2019

BD stands behind the safety of its LUTONIX® DCB and is committed to improving the quality of life for patients with PAD. To ensure patients receive the best care possible, BD’s broad range of treatment options for this serious disease will continue to be available for health care providers.

BD Announces Results for 2019 Third Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

Aug 6, 2019

BD Announces Results for 2019 Third Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

BD Statement on Georgia Facilities

Jul 25, 2019

BD Statement on Georgia Facilities

BD releases 2018 Sustainability Report

Jul 23, 2019

BD today issued its 2018 Sustainability Report, focusing on management of the environmental, social and governance factors that support the company’s 2020 Sustainability Goals.

United States and Indonesia Expand Collaboration to End Tuberculosis

Jun 27, 2019

Today, the United States Government through the United States Agency for International Development (USAID) and BD (Becton, Dickinson and Company), a U.S.-based global medical technology company, formalized a new partnership to support Indonesia in eliminating tuberculosis (TB) through its National Tuberculosis Program.

BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices

Jun 20, 2019

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting related to the potential increase in mortality associated with the use of paclitaxel-coated devices in patients with peripheral arterial disease (PAD) in the superficial femoropopliteal artery (SFA):

BD Debuts New Software for Flow Cytometry Analysis

Jun 19, 2019

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the availability of FlowJo software version 10.6 for flow cytometry data analysis.

BD Unveils New Solution for High Throughput Molecular Diagnostic Testing

Jun 18, 2019

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVDD certification of the BD COR System in Europe.

BD Announces New Leadership for BD Biosciences

Jun 17, 2019

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the appointment of Puneet Sarin to worldwide president, BD Biosciences, effective today.

New Report Sheds Light on Health Care’s ‘Hidden’ Epidemic – Hospital Drug Diversion – and its Role in the Opioid Crisis

Jun 4, 2019

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in U.S. hospitals, an underreported contributor to the opioid epidemic.

1 2 3 30

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.